Cover Image

Cimzia(克隆氏症)- 預測與市場分析

Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 297503
出版日期 內容資訊 英文 45 Pages
Back to Top
Cimzia(克隆氏症)- 預測與市場分析 Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022
出版日期: 2014年01月31日 內容資訊: 英文 45 Pages




本報告提供UCB的PEG化 抗TNFα抗體、Cimzia(certolizumab pegol)的治療方法調查分析、疾病概要和治療指南、競爭情形、產品資訊、主要國家的銷售額預測等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 症狀
  • 預測
  • QOL

第4章 疾病的管理

  • 治療概要

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 Cimzia(certolizumab pegol)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄


Product Code: GDHC323DFR

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

UCB's Cimzia (certolizumab pegol) is a PEGylated Fab' fragment of a humanized mAb with specificity for human TNF-α. The Fab' fragment of this biologic was engineered with a single free cysteine residue in the hinge region, which enables The site-specific attachment of polyethylene glycol without affecting the ability of the Fab' fragment to bind to and neutralize TNF-α. Due to the absence of the Fc region in its structure, Cimzia does not cause antibody-dependent, cell-mediated cytotoxicity. Also, in contrast to Remicade and Humira, Cimzia does not increase apoptosis, a well-known phenomenon with other anti-TNF-α agents, which may be responsible for their associated side effects.


  • Overview of Crohn's disease (CD), including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Cimzia including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Cimzia for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, China and Canada

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Cimzia performance
  • Obtain sales forecast for Cimzia from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, China and Canada)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Treatment Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Cimzia (certolizumab pegol)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed CD Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Author/Reviewer
    • 7.7.2. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Symptoms of CD
  • Table 2: Treatment Guidelines for CD
  • Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013
  • Table 4: Leading Branded Drugs Used to Treat CD
  • Table 5: Product Profile - Cimzia
  • Table 6: Cimzia SWOT Analysis, 2013
  • Table 7: Global Sales Forecasts ($) for Cimzia, 2012-2022
  • Table 8: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right)
  • Figure 2: Potential Biologic Drug Targets for CD
  • Figure 3: Patient Care Path for CD
Back to Top